Cromwell MEM, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006;8:E572–9. https://doi.org/10.1208/aapsj080366.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hermeling S, Crommelin DJA, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharmaceut Res. 2004;21:897–903. https://doi.org/10.1023/b:pham.0000029275.41323.a6.

Article  CAS  Google Scholar 

Ripple DC, Dimitrova MN. Protein particles: what we know and what we do not know. J Pharm Sci. 2012;101:3568–79. https://doi.org/10.1002/jps.23242.

Article  CAS  PubMed  Google Scholar 

Garidel P, Kuhn AB, Schäfer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–60. https://doi.org/10.1016/j.ejpb.2017.06.029.

Article  CAS  PubMed  Google Scholar 

Corvari V, Narhi LO, Spitznagel TM, Afonina N, Cao S, Cash P, et al. Subvisible (2–100 μm) Particle analysis during biotherapeutic drug product development: part 2. Experience with the application of subvisible particle analysis. Biologicals. 2015;43:457–73. https://doi.org/10.1016/j.biologicals.2015.07.011.

Article  CAS  PubMed  Google Scholar 

Narhi LO, Corvari V, Ripple DC, Afonina N, Cecchini I, Defelippis MR, et al. Subvisible (2–100 μm) particle analysis during biotherapeutic drug product development: part 1. Considerations and strategy. J Pharm Sci. 2015;104:1899–908. https://doi.org/10.1002/jps.24437.

Article  CAS  PubMed  Google Scholar 

Gross-Rother J, Blech M, Preis E, Bakowsky U, Garidel P. Particle detection and characterization for biopharmaceutical applications: current principles of established and alternative techniques. Pharmaceutics. 2020;12:1112. https://doi.org/10.3390/pharmaceutics12111112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Nema S, Teagarden D. Protein aggregation—pathways and influencing factors. Int J Pharm. 2010;390:89–99. https://doi.org/10.1016/j.ijpharm.2010.02.025.

Article  CAS  PubMed  Google Scholar 

Garidel P, Kebbel F. Protein therapeutics and aggregates characterized by photon correlation spectroscopy. BioProcess International. 2010;8:38–46.

CAS  Google Scholar 

Blech M, Melien R, Tschammer N, Presser B, Hinderberger D, Garidel P. Expanding the toolbox for predictive parameters describing antibody stability considering thermodynamic and kinetic determinants. Pharm Res. 2021;38:2065–89. https://doi.org/10.1007/s11095-021-03120-x.

Article  CAS  PubMed  Google Scholar 

Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. Classification of protein aggregates. J Pharm Sci. 2012;101:493–8. https://doi.org/10.1002/jps.22790.

Article  CAS  PubMed  Google Scholar 

Garidel P, Herre A, Kliche W. Microscopic methods for particle characterization in protein pharmaceuticals. In: Mahler HC, Jiskoot W, editors. Analysis of aggregates and particles in protein pharmaceuticals. 1st ed. Hoboken, New Jersey: John Wiley & Sons Inc; 2012. p. 269–302. https://doi.org/10.1002/9781118150573.ch12. Chapter 12.

Chapter  Google Scholar 

Moussa EM, Panchal JP, Moorthy BS, Blum JS, Joubert MK, Narhi LO, et al. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105:417–30. https://doi.org/10.1016/j.xphs.2015.11.002.

Article  CAS  PubMed  Google Scholar 

Langille SE. Particulate matter in injectable drug products. PDA J Pharm Sci Tech. 2013;67:186–200. https://doi.org/10.5731/pdajpst.2013.00922.

Article  CAS  Google Scholar 

Kijanka G, Bee JS, Korman SA, Wu Y, Roskos LK, Schenerman MA, et al. Submicron size particles of a murine monoclonal antibody are more immunogenic than soluble oligomers or micron size particles upon subcutaneous administration in mice. J Pharm Sci. 2018;107:2847–59. https://doi.org/10.1016/j.xphs.2018.06.029.

Article  CAS  PubMed  Google Scholar 

Swanson MD, Rios S, Mittal S, Soder G, Jawa V. Immunogenicity risk assessment of spontaneously occurring therapeutic monoclonal antibody aggregates. Front Immunol. 2022;13: 915412. https://doi.org/10.3389/fimmu.2022.915412.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99:3302–21. https://doi.org/10.1002/jps.22097.

Article  CAS  PubMed  Google Scholar 

Fawaz I, Schaz S, Boehrer A, Garidel P, Blech M. Micro-flow imaging multi-instrument evaluation for sub-visible particle detection. Eur J Pharm Biopharm. 2023;185:55–70. https://doi.org/10.1016/j.ejpb.2023.01.017.

Article  CAS  PubMed  Google Scholar 

Schleinzer F, Strebl M, Blech M, Garidel P. Backgrounded membrane imaging—a valuable alternative for particle detection of biotherapeutics? J Pharm Innov. 2023; 18:1–19. https://doi.org/10.1007/s12247-023-09734-5.

Article  Google Scholar 

Benkstein KD, Balakrishnan G, Bhirde A, Chalus P, Das TK, Do N, et al. An interlaboratory comparison on the characterization of a sub-micrometer polydisperse particle dispersion. J Pharm Sci. 2022;111:699–709. https://doi.org/10.1016/j.xphs.2021.11.006.

Article  CAS  PubMed  Google Scholar 

Telikepalli SN, Carrier MJ, Ripple DC, Barnett G, Bhirde A, Bolton D, et al. An interlaboratory study to identify potential visible protein-like particle standards. AAPS PharmSciTech. 2022;24:18. https://doi.org/10.1208/s12249-022-02457-9.

Article  CAS  PubMed  Google Scholar 

FDA US. Guidance for industry: immunogenicity assessment for therapeutic protein products. US FDA; 2014. https://www.fda.gov/media/85017/download. Accessed 5 Feb 2024.

Roesch A, Zölls S, Stadler D, Helbig C, Wuchner K, Kersten G, et al. Particles in biopharmaceutical formulations, part 2: an update on analytical techniques and applications for therapeutic proteins, viruses, vaccines and cells. J Pharm Sci. 2021;111:933–50. https://doi.org/10.1016/j.xphs.2021.12.011.

Article  CAS  PubMed  Google Scholar 

Europäisches Arzneibuch. 6th ed. Deutscher Apotheker Verlag. 2022, ISBN 978-3-7692-8110-1; 2022.

USP-NF 2021 Issue 1: The United States Pharmacopeia and National Formulary. 2021. https://online.uspnf.com/uspnf. Accessed 5 Feb 2024.

Gross J, Sayle S, Karow AR, Bakowsky U, Garidel P. Nanoparticle tracking analysis of particle size and concentration detection in suspensions of polymer and protein samples: influence of experimental and data evaluation parameters. Eur J Pharm Biopharm. 2016;104:30–41. https://doi.org/10.1016/j.ejpb.2016.04.013.

Article  CAS  PubMed  Google Scholar 

Vestad B, Llorente A, Neurauter A, Phuyal S, Kierulf B, Kierulf P, et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. J Extracell Vesicles. 2017;6:1344087. https://doi.org/10.1080/20013078.2017.1344087.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bachurski D, Schuldner M, Nguyen P-H, Malz A, Reiners KS, Grenzi PC, et al. Extracellular vesicle measurements with nanoparticle tracking analysis — an accuracy and repeatability comparison between NanoSight NS300 and ZetaView. J Extracell Vesicles. 2019;8:1596016. https://doi.org/10.1080/20013078.2019.1596016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim A, Ng WB, Bernt W, Cho N-J. Validation of size estimation of nanoparticle tracking analysis on polydisperse macromolecule assembly. Sci Rep. 2019;9:2639. https://doi.org/10.1038/s41598-019-38915-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huber MJ, Ivleva NP, Booth AM, Beer I, Bianchi I, Drexel R, et al. Physicochemical characterization and quantification of nanoplastics: applicability, limitations and complementarity of batch and fractionation methods. Anal Bioanal Chem. 2023;415:3007–31. https://doi.org/10.1007/s00216-023-04689-5.

Article  CAS